[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.157.19.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 648
Citations 0
Editorial
May 2016

Positive Effect on Multiple Sclerosis With Treatment of Metabolic Syndrome

Author Affiliations
  • 1Department of Neurology, Ruhr-University Bochum, St Josef–Hospital Bochum, Bochum, Germany
JAMA Neurol. 2016;73(5):499-501. doi:10.1001/jamaneurol.2015.5050

In this issue of JAMA Neurology, an open-label study by Negrotto et al1 investigates the effect of oral antidiabetic medications on paraclinical outcome measures in 50 obese patients with multiple sclerosis (MS) and metabolic syndrome. In this study, 20 patients receiving metformin hydrochloride and 10 receiving pioglitazone hydrochloride had significantly fewer new or enlarging T2 lesions or gadolinium-enhancing lesions confirmed by brain magnetic resonance imaging after about 2 years of treatment compared with a control group of 20 patients with MS and metabolic syndrome who did not receive metformin or pioglitazone.

First Page Preview View Large
First page PDF preview
First page PDF preview
×